Katrine Bosley appointed to Galapagos' Board of Directors
(Thomson Reuters ONE) -
Mechelen, Belgium; 4 March 2013 - Galapagos NV (Euronext: GLPG) announced today
the appointment of Katrine Bosley to its Board of Directors as an independent
Non-Executive Director.
Ms Bosley was appointed to fill the vacancy that has arisen on Galapagos' Board
as a result of the recent resignation of Mr Ferdinand Verdonck, who has been a
member of the Galapagos Board since the IPO of the Company in 2005.
"On behalf of the Board I sincerely thank Ferdinand for his exceptional support
of the Company during the last eight years," Raj Parekh, Chairman of the Board,
commented. "We all strongly appreciate Ferdinand's material role as a Board
member in guiding Galapagos in its evolution and transformation from a young
biotech company into a mature bio-pharmaceutical group, and we are very grateful
for his constructive and stimulating contributions over such a long period."
Katrine Bosley was until recently the CEO of Avila Therapeutics, a targeted
covalent drug company. Avila established a number of strategic alliances prior
to its acquisition by Celgene in 2012. Prior to Avila, Katrine was Vice
President Business Development at Adnexus Therapeutics, a company developing a
new class of protein therapeutics. Katrine joined Adnexus from Biogen Idec where
she had roles in business development, commercial operations, and portfolio
strategy in the U.S. and Europe. Earlier, she was part of the healthcare team
at the venture firm Highland Capital Partners. Katrine graduated from Cornell
University with a B.A. in biology and completed the Program for Management
Development at Harvard Business School.
"We are very pleased that Katrine has agreed to become a member of the Galapagos
Board of Directors. Her proven track record of scientific and business
leadership, as well as her specific expertise in matters that are of direct
importance for the Company's growth path, will make her an excellent Board
member," commented Onno van de Stolpe, CEO of Galapagos.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with a large pipeline of four clinical, six pre-clinical, and 30 discovery
small-molecule and antibody programs in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment
of rheumatoid arthritis and potentially other inflammatory diseases, about to
enter Phase 2b studies. AbbVie and Galapagos signed a worldwide license
agreement whereby AbbVie will be responsible for further development and
commercialization after Phase 2b. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-
licensed by GlaxoSmithKline in 2012). GLPG0187 is a novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis. GLPG0974 is the
first inhibitor of GPR43 to be evaluated clinically for the treatment of IBD;
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information at: www.glpg.com
Contact
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir(at)glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
Katrine Bosley appointed to Galapagos' Board of Directors:
http://hugin.info/133350/R/1682611/550450.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1682611]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Eurasian Minerals Drills 101 Meters of Oxide Averaging 1.25 g/t Gold and 7.95 g/t Silver at the Akarca Project, Northwest TurkeyDatum: 04.03.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 235253
Anzahl Zeichen: 5873
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Katrine Bosley appointed to Galapagos' Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
